Last reviewed · How we verify
NCT04211688
Effectiveness of a Combined Group-individual Schema Therapy for Borderline Personality Disorder
NA trial testing Group Schema therapy in Borderline Personality Disorder in 80 participants. Completed in 1 December 2019.
1 December 2019
Quick facts
| Lead sponsor | Consorci Sanitari del Maresme |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 12 January 2017 |
| Primary completion | 1 December 2019 |
| Estimated completion | 1 December 2019 |
Drugs / interventions tested
- Group Schema therapy
- Individual Schema therapy
Conditions studied
- Borderline Personality Disorder — all drugs for Borderline Personality Disorder →
- Randomized Controlled Trial — all drugs for Randomized Controlled Trial →
Sponsor
Consorci Sanitari del Maresme
Who can join
Adults 18 to 65, any sex, with Borderline Personality Disorder or Randomized Controlled Trial. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background and Objectives: Schema therapy has been shown to be of benefit in treating borderline personality disorder. However, it is still unclear what the most suitable treatment implementation format is and to what extent therapeutic gains may be generalizable to regular healthcare settings with limited resources. Methods: A pragmatic randomized controlled trial was conducted ona representative Spanish sample of outpatients with a DSM-5 main diagnosis of borderline personality disorder. Patients were allocated either to a combined (group plus individual) schema therapy format (n=40) or to a group-only schema therapy format (n=40). Borderline personality disorder severity was the primary outcome, with other clinical variables considered as secondary outcomes (e.g., early maladaptive schemas, functioning). The assessment protocol included baseline, post-treatment (after 12months of treatment), and six-month follow-up evaluations. Data was analyzed through a two-way repeated measures ANOVA. Limitations were a limited follow-up assessment and the absence of multi-center data that detracted from the long-term stability and generalizability of the findings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04211688
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Borderline Personality Disorder
Currently open trials in the same condition.
- NCT06458933 — Testing Interventions for Borderline Personality Disorder. · Phase 2 · recruiting
- NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
- NCT07119541 — Testing an Alliance-Focused Dialectical Behaviour Therapy Training for Borderline Personality Disorder · NA · active not recruiting
- NCT06446765 — Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder · Phase 2 · recruiting
- NCT07197502 — Treatment of Borderline Personality Disorder With rTMS · NA · recruiting
Other Consorci Sanitari del Maresme trials
Trials by the same sponsor.
- NCT04519008 — Effectiveness and Security Testing of a Mobile App · NA · not yet recruiting
- NCT06925880 — Effect of Micronized Creatine Monohydrate on Muscle Mass, Strength and Performance in Older Adults Submitted to Total Kn · NA · recruiting
- NCT07252817 — Intensive Monitoring of Post-surgery Pain in Major Ambulatory Surgery · NA · completed
- NCT06497426 — Efficacy of a Water Intervention in Institutionalized Aged Population. · NA · completed
- NCT06507098 — Effectiveness of Telematic Instruction to Patients in the Correct Performance of Respiratory Polygraphy at Home · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04211688 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Consorci Sanitari del Maresme
- Last refreshed: 26 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04211688.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing